Topic:Subcutaneous Administration
Subcutaneous administration in horses involves the delivery of medication or other substances into the tissue layer between the skin and muscle. This method is used for various therapeutic and preventative treatments, including vaccinations, analgesics, and fluid administration. The technique requires careful consideration of factors such as needle size, injection site, and volume of the substance to ensure effective absorption and minimize discomfort or complications. Subcutaneous administration is often chosen for its ease of application and potential for sustained release of medication. This page compiles peer-reviewed research studies and scholarly articles that explore the methodology, efficacy, and applications of subcutaneous administration in equine veterinary practice.
Antidotal effect of vitamin K1 against warfarin-induced anticoagulation in horses. Warfarin-induced anticoagulation and reversal of the induced anticoagulation by vitamin K1 were evaluated in 4 mature horses. Each horse was given warfarin IV until the prothrombin (PT) time was prolonged by approximately 1.5 times the predosing base-line value. In experiment 1, we evaluated the time required for PT to return to the predosing value (PT reversal time) after warfarin administration was discontinued. Between each experiment, a 1-week rest period was allowed. In experiment 2, two doses of vitamin K1 (100 mg/dose) were administered IM 6 hours apart, and the PT was monitored hourly ...
Effects of prostaglandin F2alpha on the oestrous cycle and pregnancy in mares. Several experiments indicated that prostaglandin F2alpha (PGF2alpha) has luteolytic and abortifacient properties in mares. A single subcutaneous injection of 1-25 mg PGF2alpha on Day 6 of dioestrus was as effective as 10 mg PGF2alpha in inducing luteolysis. Oestrus and ovulation appeared to be synchronized when a single injection of 1-25 mg PGF2alpha was given on Days 7, 10 or 13 after ovulation but not on Days 1 or 4 after ovulation or on Day 2 of oestrus. Intramuscular administration was as effective as subcutaneous administration and 1-25 mg PGF2alpha was the minimal effective systemic dose...
Control of estrus with prostaglandin F2alpha in mares: minimal effective dose and stage of estrous cycle. To determine the minimal effective dose of prostagiandin (PGF2alpha; tromethamine salt) given subcutaneously (SC), mares of mixed breeding (400 kg av body weight) were given 2-, 3-, 5-, and 10-mg doses from 7 to 9 days after ovulation. In some but not all mares given doses of 2 and 3 mg of PGF2alpha, luteolysis occurred, but doses of 5 or 10 mg of PGF2alpha were luteolytic in all mares. The 10-mg dose of PGF2alpha did not cause luteolysis in mares 1 day after ovulation, and caused luteolysis in only 2 of 5 mares on day 3 after ovulation. The same dose of PGF2alpha, however, caused luteolysis i...